摘要
目的：研究分析替吉奥对晚期转移性乳腺癌患者的治疗效果及应用的安全性。方法：晚期转移性乳腺癌患者19例,单独使用替吉奥作为临床治疗药物,剂量为40~60mg口服。统计观察患者的治疗效果与治疗过程中发生的不良反应,对比患者治疗前后的CA153。结果：19例患者治疗后,CA153均有明显的降低,与治疗前比较差异明显,P〈0.05;19例患者中,CR0例,PR5例,SD7例,PD6例,1例患者死亡。患者发生的不良反应主要为胃肠道不良反应、骨髓抑制,以Ⅰ度和Ⅱ度为多数,1例患者出现了Ⅲ度的白细胞减少。结论：使用替吉奥治疗晚期转移性乳腺癌的疗效较好,有助于降低患者的CA153,不良反应少。
Objective： To analyze the therapeutic effect and safety of application of breast cancer patients in advanced study of S-1. Methods： 19 cases of advanced metastatic breast cancer patients, used alone S-1 as clinical treatment drug, dose of 40~60mg orally. The adverse reaction of statistical observation of patients treatment effect and the treatment process, before and after treatment in patients with contrast CA153. Results： 19 patients after the treatment, CA153 were significantly lower, compared with that before treatment is significantly different, P〈0.05; in 19 cases, CR0 cases, PR5 cases, SD7 cases, PD6 cases, 1 cases of death. The main adverse reactions occurred in patients with gastrointestinal adverse reactions, bone marrow suppression, to I degrees and II degrees for the majority, 1 patients with III of the white blood cell reduction. Conclusion：The good effect using S-1 in treatment of advanced metastatic breast cancer, help to reduce patient CA153, less adverse reaction.
出处
《中国医药导刊》
2014年第11期1410-1411,共2页
Chinese Journal of Medicinal Guide
